<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214019</url>
  </required_header>
  <id_info>
    <org_study_id>H-2003-0469</org_study_id>
    <nct_id>NCT00214019</nct_id>
  </id_info>
  <brief_title>The Effect of Salmeterol on Eosinophil (EOS) Function</brief_title>
  <official_title>The Effect of Salmeterol on Eosinophil (EOS) Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or
      the combination treatment with fluticasone and salmeterol, is associated with a greater
      number of sputum eosinophils following antigen challenge and, under these circumstances, the
      migrating peripheral blood eosinophils are less adherent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An antigen challenge is when a participant inhales either cat, ragweed, or dust dander in
      increasing concentrations until their lung function drops 15 or 20 percent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge</measure>
    <time_frame>Eosinophils are measured 24 hours after the subject has an antigen challenge</time_frame>
    <description>Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo Diskus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol Diskus 50 mcg twice per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol Diskus 50 mcg twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo diskus, fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo diskus, fluticasone MDI 88 mcg twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol, Fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <description>salmeterol diskus 50 mcg twice per day</description>
    <arm_group_label>Salmeterol Diskus 50 mcg twice per day</arm_group_label>
    <arm_group_label>Salmeterol, Fluticasone</arm_group_label>
    <other_name>Seravent</other_name>
    <other_name>Advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>placebo diskus, fluticasone MDI 88 mcg twice per day</description>
    <arm_group_label>Placebo diskus, fluticasone</arm_group_label>
    <arm_group_label>Salmeterol, Fluticasone</arm_group_label>
    <other_name>flovent</other_name>
    <other_name>advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo diskus</description>
    <arm_group_label>Placebo Diskus</arm_group_label>
    <other_name>no drug</other_name>
    <other_name>comparator treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-55 years of age

          -  history of asthma symptoms for the previous 6 months

          -  Forced Expiratory Value (FEV1) &gt;75% of predicted

          -  positive prick skin test to cat, house dust mite or ragweed

        Exclusion Criteria:

          -  history of life threatening asthma or anaphylaxis

          -  current smoker

          -  pregnant or breast-feeding

          -  evidence of an upper respiratory infection within 4 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>August 17, 2011</results_first_submitted>
  <results_first_submitted_qc>June 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2016</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at UW Hospital and Clinics, Madison, WI from November 2003 to January 2008.</recruitment_details>
      <pre_assignment_details>6 participants completed all four arms of the study. 36 participants were recruited; 17 screen failed prior to randomization, 11 were lost to follow up prior to randomization, and 2 withdrew consent prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All participants completed all 4 arms of the study. 28 days per arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo/Placebo Arm</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo/Salmeterol Arm</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Fluticasone/Placebo Arm</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Fluticason/Salmeterol Arm</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failed prior to randomization</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a randomized/double-blinded/placebo-controlled/four-phase/crossover trial in subjects with a history of mild allergic asthma. Treatment arms included placebo, fluticasone 44 µg twice daily, salmeterol 50 µµg twice daily and combined FT and SA treatment, all given by inhalers. The order of these treatments was randomized for each subject.</population>
      <group_list>
        <group group_id="B1">
          <title>4 Way Cross Over</title>
          <description>Participants completed all 4 arms:
Placebo, Salmeterol diskus 40 mcg twice per day, Placebo then fluticasone, Salmeterol then Fluticasone,</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge</title>
        <description>Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.</description>
        <time_frame>Eosinophils are measured 24 hours after the subject has an antigen challenge</time_frame>
        <population>Participants for analysis included any subject that completed that specific treatment phase, even if they did not complete other treatment phases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Placebo</title>
            <description>Participants on Placebo/Placebo arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Salmeterol</title>
            <description>Participants on Placebo/Salmeterol arm</description>
          </group>
          <group group_id="O3">
            <title>Placebo/fFuticasone</title>
            <description>Participants on Placebo/Fluticasone arm</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol/Fluticasone</title>
            <description>Participants on Salmeterol/Fluticasone</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge</title>
          <description>Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.</description>
          <population>Participants for analysis included any subject that completed that specific treatment phase, even if they did not complete other treatment phases.</population>
          <units>Eosinophil percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.4"/>
                    <measurement group_id="O2" value="2.4" spread="3.4"/>
                    <measurement group_id="O3" value="0.54" spread="0.39"/>
                    <measurement group_id="O4" value="2.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.5 years</time_frame>
      <desc>Subject interview at visit</desc>
      <group_list>
        <group group_id="E1">
          <title>4 Way Cross Over</title>
          <description>Participants completed all 4 treatments:
Placebo Salmeterol diskus 50 mcg twice per day Placebo then Fluticasone Salmeterol then Fluticasone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Spasm</sub_title>
                <description>ARM: Fluticasone/Salmeterol</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>ARM: Fluticasone/Placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased asthma symptoms</sub_title>
                <description>ARM: Placebo/Salmeterol</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Scratchy throat</sub_title>
                <description>ARM: Fluticasone/Placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Fainted</sub_title>
                <description>ARM: Fluticasone/Placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>36 subjects were screened, identifying subjects with both a peripheral eosinophil count &gt;0.200x106 cells/ml and a LPR &gt;15% was more difficult than expected. Of the subjects screened, only 12 met criteria and 6 subjects completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gina Crisafi</name_or_title>
      <organization>UW Madison</organization>
      <phone>6082654554</phone>
      <email>gmc@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

